Page 94 | Certara

On-Demand Webinar

Antibody-drug Conjugates in the Clinic: Key Considerations & the Role of Modeling in Expediting Development

Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…

CertaraApril 17, 2023

Case Study

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…

CertaraApril 17, 2023

Blog

Stepwise PIPs: A Solution for the Challenges of Pediatric Drug Development

Early paediatric investigation plan (PIP) submissions – an unnecessarily bitter medicine? In the European Union…

CertaraApril 14, 2023

White Paper

Why Performing Key CMC Activities Early Can Aid De-risking Your Drug Development Program

This white paper focuses on best practices for developing a CMC strategy for orally administered…

CertaraApril 13, 2023

Case Study

Repurposing Data & Advanced Analytics to Validate Surrogate Endpoints

Repurposed data and advanced analytics can be used to validate a surrogate endpoint. A surrogate…

CertaraApril 13, 2023

Press Coverage

LABO: Data utilisation and data infrastructure in drug development: Data, Data, Data

Published: April 12, 2023 This is the German article written by Dr. Fabian Rauscher, Scientific…

CertaraApril 12, 2023

Video

Milestone Achieved: Simcyp 100

CertaraApril 11, 2023

Brochure

Drug Discovery & Development with Deep Learning Advanced Analytics

Solutions to Meet All Needs: From Small Biotech to Large Global Pharma

CertaraApril 6, 2023

Blog

Considerations for Pricing & Formulary Access for DRG-Funded Hospital Drugs

In the United States, treatments or medical services that require the patient be admitted into…

CertaraApril 6, 2023

Case Study

Using Real World Evidence to Inform Treatment Guidelines

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

CertaraApril 5, 2023

Antibody-drug Conjugates in the Clinic: Key Considerations & the Role of Modeling in Expediting Development

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Stepwise PIPs: A Solution for the Challenges of Pediatric Drug Development

Why Performing Key CMC Activities Early Can Aid De-risking Your Drug Development Program

Repurposing Data & Advanced Analytics to Validate Surrogate Endpoints

LABO: Data utilisation and data infrastructure in drug development: Data, Data, Data

Milestone Achieved: Simcyp 100

Drug Discovery & Development with Deep Learning Advanced Analytics

Considerations for Pricing & Formulary Access for DRG-Funded Hospital Drugs

Using Real World Evidence to Inform Treatment Guidelines

Newsletter sign up

Quick links

Solutions

Contact